辛伐他汀对绝经伴血脂代谢异常女性跟骨骨密度的影响

目的 研究辛伐他汀对绝经后伴血脂代谢异常女性跟骨骨密度的影响。方法 分析885名绝经后口服辛伐他汀治疗血脂代谢异常（TC>5.18mmol/L 或 LDL-C> 3.37mmol/L）女性的跟骨骨密度，并依据T值分为骨质正常、骨量减少、骨质疏松。结果 治疗前跟骨骨密度为305.3± 59.2 mg/cm2，骨质正常、骨量减少、骨质疏松的人数分别为115、446、324，口服辛伐他汀（20mg/d）治疗3月后骨密度为309.7±56.3 mg/cm2，骨质正常、骨量减少、骨质疏松的人数为117、459、319，12月后跟骨骨密度为312.5±60.9 mg/cm2，骨质正常、骨量减少、骨质疏松的人数为122、460、303。结论 绝经后伴血脂代谢异常女性应用辛伐他汀（20mg/d）治疗12个月后跟骨骨密度增高，但对骨质疏松患病风险无影响。

Effect of simvastatin on bone mineral density of the calcaneus in postmenopausal women with hyperlipoidemia

Objective To evaluated the effect of simvastatin on bone mineral density (BMD) of the calcaneus in postmenopausal women with hyperlipidemia. Methods BMD of the calcaneus of 885 postmenopausal women with hyperlipidemia (TC>5.18mmol/L or LDL-C>3.37mmol/L) were studied. Simvastatin was used in these women. According to the T-score, normal bone mass, osteopenia, and osteoporosis were diagnosed. Results BMD of the calcaneus was 305.3± 59.2 mg/cm2 before the treatment. The number of people with normal bone mass, osteopenia, and osteoporosis were 115, 446, and 324, respectively. After simvastatin administration (20 mg/d) for 3 months, the BMD was 309.7±56.3mg/cm2. The number of people with normal bone mass, osteopenia, and osteoporosis were 117, 459, and 319, respectively. After a 12-month treatment, BMD of the calcaneus was 312.5±60.9 mg/cm2. The number of people with normal bone mass, osteopenia, and osteoporosis were 122, 460, and 303, respectively. Conclusion After a 12-month simvastatin (20mg/kg/d) administration, BMD of the calcaneus increases in postmenopausal women with hyperlipidemia. It can not affect the risk of osteoporosis for these women.